• Chang-E Ma, Pei Yu, Wei Wei, and Xiao-Qin Chen.
• Department of Endocrinology.
• Medicine (Baltimore). 2021 Jun 4; 100 (22): e25991e25991.

BackgroundSeveral studies have reported good results for angiotensin II receptor blockers (ARB) combined with tripterygium glycosides (TGs) in the treatment of diabetic nephropathy (DN). However, because a small number of cases were included in each study, the statistical power was limited. Therefore, we performed a protocol for meta-analysis to further evaluate the clinical efficacy and safety of combined ARB and TGs in treatment of DN.MethodsThe protocol was written following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines. We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, Science Direct up to April 2021. Outcome measures were 24-h urinary total protein, urinary albumin excretion rate, serum creatinine, blood urea nitrogen, albumin, hemoglobin A1c, β2-microglobulin and serum glutamic pyruvic transaminase. The risk of bias assessment of the included studies was performed by two authors independently using the tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). We performed meta-analysis using STATA 11.0.ResultsThe review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.ConclusionThe findings will provide helpful evidence for the application of combined ARB and TGs in the treatment of DN.Osf Registration Number10.17605/OSF.IO/ARGE3.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

22 keywords...

hide…